Evaluation of the Glasgow Prognostic Score (GPS) in advanced gastric cancer patients undergoing gastro-jejunostomy

295 Background: Several biomarkers based on serum chemistry have been reported to be associated with the prognosis of several types of cancers. This retrospective study aimed to investigate the prognostic value of preoperative mGPS and NLR after curative resection for gastric cancer. Methods: A total of 295 patients who underwent curative gastrectomy for primary gastric cancer at our institution from January 2013 to December 2017 were enrolled in this study. The mGPS was calculated by CRP and Alb using standard thresholds ( > 0.5 mg/dL for CRP and < 3.5 g/dL for Alb). The NLR was defined as absolute neutrophil count divided by absolute lymphocyte count. The survival curves of patients stratified by each parameter were plotted by the Kaplan-Meier method and compared by log-rank test. Multivariate Cox proportional hazards regression models were used to select parameters independently correlated with prognosis. Results: The median follow-up time was 36.7 months, and 29 patients died during follow-up. The estimated 5-year survival rate was 83.1%. Results from the univariate analyses showed mGPS2 (CRP > 0.5 mg/dL and Alb < 3.5 g/dL) was associated with poor survival while NLR and NLRc was not (P < 0.001, P = 0.506, and P = 0.423, respectively). In the multivariate analyses, the mGPS2 was identified as an independent predictive factor for OS in gastric cancer patients after curative resection (HR: 2.624; 95% CI: 1.058-6.505; P = 0.037). Conclusions: Preoperative mGPS2 was associated with worse survival after curative resection of gastric cancer patients. Based on our study, those with mPGS2 may be warranted to receive additional therapy or nutritional support to acquire better survival.

Download Full-text

Inflammation-Based Scoring System (Glasgow Prognostic Score) Is a Significant Prognostic Factor for Survival in Stage IV Gastric Cancer Patients

The American Journal of Gastroenterology ◽

10.14309/00000434-201510001-02450 ◽

2015 ◽

Vol 110 ◽

pp. S1016

Author(s):

Hiroyuki Baba ◽

Koki Kuwabara ◽

Toru Ishiguro ◽

Minoru Fukuchi ◽

Yoichi Kumagai ◽

...

Keyword(s):

Gastric Cancer ◽

Prognostic Factor ◽

Cancer Patients ◽

Scoring System ◽

Prognostic Score ◽

Glasgow Prognostic Score ◽

Stage Iv ◽

Significant Prognostic Factor ◽

Stage Iv Gastric Cancer ◽

Gastric Cancer Patients

Download Full-text

Pretreatment Glasgow prognostic score as a predictor of outcomes in nivolumab-treated patients with advanced gastric cancer

PLoS ONE ◽

10.1371/journal.pone.0247645 ◽

2021 ◽

Vol 16 (2) ◽

pp. e0247645

Author(s):

Nagahiro Tokuyama ◽

Naoki Takegawa ◽

Michiko Nishikawa ◽

Aya Sakai ◽

Takuya Mimura ◽

...

Keyword(s):

Gastric Cancer ◽

Overall Survival ◽

Advanced Gastric Cancer ◽

Median Overall Survival ◽

Prognostic Score ◽

Glasgow Prognostic Score ◽

Prognostic Scores ◽

Cancer Center ◽

Number Of Patients ◽

The Glasgow Prognostic Score

In Japan, South Korea, and Taiwan, nivolumab might provide overall survival benefits for patients with advanced gastric cancer. However, it is effective only in a limited number of patients. The Glasgow prognostic score is an indicator of the systematic inflammatory response and nutritional status. This study aimed to investigate the ability of the Glasgow prognostic score and other markers to predict the outcomes of patients treated with nivolumab. We reviewed the medical records of patients treated for advanced gastric cancer and who received nivolumab between February 2015 and June 2019 at Hyogo Cancer Center. The patients were categorized into two groups according to their Glasgow prognostic scores. Overall, 53.3% and 46.7% of the patients were assigned to groups with Glasgow prognostic scores of 0 and 1/2, respectively. The median durations of progression-free and overall survival of the participants were 2.3 and 5.7 months, respectively. The patients with a Glasgow prognostic score of 0 had significantly higher median overall survival than those with scores of 1 or 2 (16.4 vs. 4.2 months; p = 0.0006). This observation suggests that a pretreatment Glasgow prognostic score of 0 is associated with better outcomes, and this scoring system may be used as a predictor of outcomes in patients with advanced gastric cancer treated with nivolumab.

Download Full-text

Use of inflammation-based prognostic score to predict survival in patients with advanced gastric cancer receiving biweekly docetaxel and S-1 combination chemotherapy.

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.15_suppl.e14624 ◽

2012 ◽

Vol 30 (15_suppl) ◽

pp. e14624-e14624

Author(s):

Chikara Kunisaki ◽

Masazumi Takahashi ◽

Hidetaka Ono ◽

Takashi Oshima ◽

Shoichi Fujii ◽

...

Keyword(s):

Gastric Cancer ◽

Prognostic Factor ◽

Advanced Gastric Cancer ◽

Cancer Patients ◽

Prognostic Score ◽

Univariate Analysis ◽

Prospective Trial ◽

Hazard Model ◽

Gastric Cancer Patients ◽

The Impact

e14624 Background: The Glasgow Prognostic Score (GPS), an inflammation-based prognostic score composed of C-reactive protein (CRP) and albumin measurements, has been reported to be a prognostic factor in patients with various cancers. This study was conducted to determine the prognostic value of GPS for patients with advanced cancer. Methods: The GPS was classified according to a previous study. A total of 83 advanced gastric cancer patients receiving bi-weekly docetaxel/S1 treatment (DS) were included. Correlation of clinicopathological factors and the GPS was assessed. To identify the impact of GPS as prognostic factors for disease-specific survival (DSS) and progression-free survival (PFS), univariate and multivariate analyses were performed. Results: Of these 83 patients, unresectable tumors were observed in 78 patients and recurrent tumors were detected in 5 patients. Of these, 13 patients underwent surgery and 12 patients underwent gastrectomy. There were significant correlations between the GPS and the neutrophil to lymphocyte ratio (NLR). Univariate analysis revealed that the GPS, ECOG-PS and gastrectomy after DS treatment significantly affected prognosis. The Cox proportional regression hazard model showed that the GPS, age and gastrectomy independently influenced DSS, and that the GPS and gastrectomy also influenced PFS. The Cox proportional regression hazard model restricted patients without gastrectomy showed that the GPS and age independently influenced DSS, and that the GPS influenced PFS. Conclusions: The GPS may be an useful prognostic factor for advanced gastric cancer patients receiving uniform first-line treatment (DS). The impact of the GPS should be confirmed in a well-designed prospective trial in many patients.

Download Full-text